veteranstoday.com

Moderna Vaccine Patented 9 Months Before Pandemic. Thanks to the Fauci-Baric' Manmade SARS Viruses – Veterans Today

Fabio Giuseppe Carlo Carisio

19-24 minutes

A disturbing document had already emerged proving the existence of an experimental gene serum based on messenger RNA against Covid-19 on 12 December 2019.

But nothing appears compared to the terrible secrets about the Spikevax vaccine produced by Big Pharma Moderna in Cambridge (Massachusetts, USA) thanks to the money of the Bill & Melinda Gates Foundation, the Pentagon (the American Department of Defense) and the collaboration with

the Niaid (Institute Allergy and Infectious Diseases National Park) headed by Anthony Fauci, White House advisor on the SARS-Cov-2 pandemic.

Patent US10702600 for the vaccine candidate mRNA-1273 was in fact registered in its new composition on March 28, 2019.

That is 9 months before the official outbreak of the Covid-19 pandemic in China and the availability of the official Wuhan sequence MN908947.1, the virus initially called 2019-nCoV and then renamed by the World Health Organization SARS-Cov-2 to the strong genomic identity with SARS of 2003 (Severe Acute Respiratory Syndrome, or Severe Acute Respiratory Syndrome, when virus and disease were called the same).

The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

The Fauci Covid-19 Dossier prepared by Dr. David E. Martin

This revelation comes from “The Fauci / COVID-19 Dossier” prepared by the American doctor David E. Martin who has developed a colossal study on US government-funded patents in relation to Coronaviruses since 2000, so much so that he suspects that SARS too in 2003 was built in the laboratory by microbiologist Ralph Baric of the Chapel Hill research center of the University of North Carolina (UNC) under the aegis of Fauci himself.

As we will see after long but inevitable premises, the registration of Moderna’s experimental vaccine on March 28, 2019 is also confirmed by the official history stored in the patent …

The discovery becomes even more disturbing in light of the fact that such research was conducted by the pharmaceutical company at the same time as Baric’s extremely dangerous experiments on SARS recombinant viruses conducted together with the director of the Infectious Diseases Research Center of the Wuhan Institute of Virology, Shi Zhengli, not

randomly dubbed in China “BatWoman” for its coronavirus tests of horseshoe bats.

As anticipated before the online investigation in the book WuhanGates (December 2020), they would be the godfathers and progenitors of a huge plot of the New World Order of ancient British Masonic origin hatched under the sign of the Chinese Communists and American Democrats.

To it were also added the peremptory paws of Italy and Saudi Arabia aimed at global immunization projects preparatory to the health dictatorship of the Covid-19 emergency and the promotion of experimental anti-Covid gene serums for the enrichment of Big Pharma and speculation of the same investment funds that control the Weapons Lobby.

THE THERAPY OF DONNO AFFOSSED BY THE MODERN GROUP

Before briefly summarizing the many information contained in the WuhanGates 40 report on the researches of Professor Baric and Doctor Fauci,

coordinator of all the most risky and secret experiments on viruses and bacteriological weapons in the 28 American civil and military laboratories as evidenced by the exclusive investigation by Gospa News, we recall another of the mysteries in the ambiguous fight against Covid-19 revealed only by our online newspaper.

Moderna is part of that colossal international Zacks group that became interested in the highly effective therapy against Covid-19 of hyperimmune plasma developed by Professor Giuseppe De Donno and mysteriously vanished in the maze of health policy before his mysterious suicide.

It should also be remembered that the experimental gene sera were able to obtain emergency authorization in the USA, from the Food and Drug Administration which, however, in recent weeks gave definitive ok to Spikevax after having granted it to Comirnaty of Pizer-Biontech amid a thousand controversies for not having subjected the clinical data to the scrutiny of the independent Advisory Committee, and in the European Union by the European Medicines Agency (where they remain

with a conditional marketing authorization as still experimental) only by virtue of two factors.

The pandemic has resulted in millions of deaths in the world with Covid-19 (in the minority died from Covid-19 and in the majority from complications of other diseases), in Italy and in other countries mainly due to inadequate home and hospital care such as the betrayal. use of cortisone or the disputed hydroxychlorichine (adopted by the protocols of the Piedmont Region) and the absence of drugs recognized as effective.

Therefore, the stop of the De Donno therapy, successfully carried out in over one hundred American university hospitals as recalled by the Johns Hopkins University in its defense, represented one of the obstacles in alternative treatments functional to the promotion of Moderna and other Big Pharma's anti-Covid vaccines.

EXPERIMENTS ON CHIMERIC VIRUSES BEFORE 2003

«The National Institute of Health's grant AI23946-08 issued to Dr. Ralph Baric at the University of North

Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci's NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit».

As Martin's dossier reports, in one of several articles derived from the work sponsored by this grant, «Baric published what he reported to be the SARS CoV full-length cDNA in which it was clearly stated that SAR CoV was based on a compound. of DNA segments».

«**Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones».**

SARS-Cov of 2003 was indicated with the name of Carlo Urbani, the researcher who was analyzing all its characteristics and died prematurely, struck down by the respiratory syndrome, like other scientists who died mysteriously while working on chimeric virus tests (Franc Plummer in Canada) or when they tried to investigate the origin of these viruses and the gene sera then placed on the market after SARS-Cov-2 (Franco Trinca and Domenico Biscardi and finally the elderly Luc Montagnier).

For the sake of brevity, let's skip all the references to the patents already mentioned in WuhanGates 40 and come to the conclusions of "The Fauci / Covid-19 Dossier" published by Dr. Martin: «In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans».

The allusion to the virus that killed the Italian scientist Urbani intent on studying it is very heavy: even SARS 2003 could have been created in the laboratory!

The National Institutes of Health, Allergy and

Infectious Diseases worked on SARS Reverse Genetics. study AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. Then, subsequently, the same NIAID carries out the research Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million.

On November 22, 2004, the University of Hong Kong patents the spike protein associated with SARS on CoV and pursues US patent 7,491,489. But on June 2005 also the Pentagon's DARPA (Defense Advanced Research Projects Agency) gets in on the game Synthetic Coronaviruses with the event Biohacking: Biological Warfare Enabling Technologies, organized in Washington, DC. and sponsored by DARPA/MITRE.

In 2008, funding for Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC

Chapel Hill. Where, in the laboratories of North Carolina University, the experiments on chimeric superviruses will be carried out between 2014 and 2017, conducted in spite of Barack Obama's moratorium on gains in function. And in 2010 the "Biodefense Grant U54 AI057157" continues with $ 8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID). Patent issuance for the SARS coronavirus patents peaked after the outbreak in Asia with 391 patents issued.

We are talking about research funded by DARPA and the Pentagon precisely because they are dedicated to the construction of recombinant viruses, especially SARS infected with HIV as happened with the plasmids built by the Wuhan Institute of Virology thanks to a funding from the European Commission chaired by Romano Prodi, with an increase in the charge. viral through the extremely dangerous Gain of Function technique and with "dual use" purposes, i.e. vaccine but also a military bacteriological weapon: as is the SARS-Cov-2 according to a sworn report drawn up by Professor Montagnier and filed in a legal action by

two lawyers British.

«The CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016» reads in The Fauci / COVID-19 Dossier.

INTRIGUE WITH THE CIA AND US INTELLIGENCE

«By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID's funded work in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response» remembered Martin.

In the same years, the Obama-Biden administration chooses lawyer Avril as deputy director from the Central Intelligence Agency, the American CIA counter-espionage which is also responsible for the supervision of military projects and which often uses the government agency USAID as a financial instrument for occult international operations. Haines, an expert in drones but also in biological weapons.

Haines, subsequently, not only in 2018 prophesied a coronavirus epidemic that could only be faced with a new “World Order” but will be one of the main protagonists of the Event 201 exercise held in mid-October in New York thanks to funding from the World Economic Forum by Klaus Schwab (Great Reset) and the Bill & Melinda Gates Foundation.

On the recommendation of the American President Joseph Biden (her longtime political friend) on 21 January 2021 she was appointed by the Senate National Director of Intelligence from where she coordinates all 17 military and civil intelligence agencies and from where she searched, without success. for a rift between 007, to refute the thesis

of the artificial origin of SARS-Cov-2.

MODERN STUDIES IN THE SAME YEARS

«By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research» the dossier still reads in reference to the experiments conducted in a "China-US affair" as Montagnier claimed on the origin of laboratory SARS-Cov-2.

«In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417» reveals Dr. Martin.

«ON 2015 Moderna signs an agreement for the development of vaccines with NIAID and executes it with the head of the developer and main inventor

mRNA-1273 Giuseppe Ciaramella» says Dr. Martin referring to the “prototype” of the experimental antiCovid gene serum named in 2020 Spikevax.

«ON 2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report. In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013»,

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

«M · CAM and Knowledge Ecology International (Martin's reference bodies – ed) have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government's funding interest in their patents and patent applications» reads in The Fauci / Covid-19 Dossier.

«While this negligence impacts all of Moderna's over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 ('600) which is the patent relating to, "a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle».

We have dedicated a long investigation to the mysterious and dangerous biotechnologies with lipid nanoparticles with extensive scientific documentation in relation to the Comirnaty messenger RNA gene serum ("heterozygous twin" of Spikevax), produced by the New Yorker Pfizer with the German Biontech: the first partner of the London-based GSK run by a Microsoft director, the second funded by the same IT tycoon Gates.

THE VACCINE PATENTED 9 MONTHS BEFORE THE PANDEMIC

In addition to the patents cited by the USPTO in their examination of '600, M·CAM has identified fourteen other issued patents preceding the '600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.

«In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified» concludes the medical author of The Fauci / Covid-19 Dossier.

But now comes the explosive statement: «**The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 –**

9 months before the SARS CoV-2 outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent» is Dr. Martin's shocking revelation.



Confidential Disclosure Agreement

In order to protect confidential information relating to research, development, business plans, and other technology, which may be disclosed between them, the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health ("NIAID"), and the "Collaborator" identified below (individually, a "Party"; collectively the "Parties"), intending to be legally bound as of the date of the last signature hereto ("Effective Date"), agree that:

1. A Party ("Disclosing Party") may disclose information to the other ("Receiving Party") for the purpose of assessing their interest in research collaboration (the "Purpose"). The Disclosing Parties are: **NIAID; Moderna Therapeutics, Inc. and its affiliates,** Proprietary Info (the "Collaborator").

2. The Parties' representatives for disclosing or receiving information (if known):

For NIAID: Barney Graham and other employees and contractors of NIAID as needed to fulfill the Purpose.

For Collaborator: Giuseppe Ciaramella, Stephane Bancel, Lee Cooper, and other employees of the Collaborator as needed to fulfill the Purpose

3. The information disclosed under this Agreement ("Confidential Information") includes any and all technical, business and financial information, including third party information, relating to the Disclosing Party, including but not limited to: (a) non-public patent applications; Proprietary Info and (c) other proprietary information, ideas, gene sequences, samples, chemical compounds, biological materials, techniques, works of authorship, non-public inventions, know-how and processes related to the current, future, and proposed products and/or services of the Disclosing Party or its partners, and including without limitation, information concerning research, experimental work, development, design details and specifications, engineering, financial information, procurement requirements, purchasing, manufacturing, customer lists, investors, employees, business and contractual relationships, business forecasts, analyst reports, marketing plans and any additional non-public information that the Disclosing Party provides.

The Confidential Information disclosed under this Agreement is described as:

For NIAID: NIAID's proprietary information and data relating to the development of vaccines for HIV, influenza, Ebola and MERS and development of broadly neutralizing monoclonal antibodies for preventative and therapeutic use.

For Collaborator: Moderna's proprietary and confidential information related to design and manufacture of a messenger RNA platform and messenger RNA constructs for treatment and prevention of disease.

4. The Receiving Party will not disclose the Confidential Information of the Disclosing Party to any person except its employees, consultants, contractors, directors, or professional advisors or authorized representatives to whom it is necessary to disclose the Confidential Information for the Purpose described above, and any such disclosures shall be under terms at least as restrictive as those specified herein. Any of the persons mentioned above who are given access to the Confidential Information shall be informed of this Agreement. The Receiving Party shall protect the Confidential Information by using the same degree

{00016216.1} Confidential Disclosure Agreement
NIAID Ref. No. 2015-33448

Moderna Therapeutics, Inc./VRC
Page 1 of 4

US010702600B1

(12) **United States Patent**
Ciaramella et al.

(10) **Patent No.: US 10,702,600 B1**
(45) **Date of Patent: Jul. 7, 2020**

(54) **BETACORONAVIRUS MRNA VACCINE**

(71) Applicant: **ModernaTX, Inc.**, Cambridge, MA (US)

(72) Inventors: **Giuseppe Ciaramella**, Sudbury, MA (US); **Sunny Himansu**, Winchester, MA (US)

(73) Assignee: **ModernaTX, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/805,587**

(22) Filed: **Feb. 28, 2020**

Related U.S. Application Data

(63) Continuation of application No. 16/368,270, filed on Mar. 28, 2019, which is a continuation of application No. 16/040,981, filed on Jul. 20, 2018, now Pat. No. 10,272,150, which is a continuation of application No. 15/674,599, filed on Aug. 11, 2017, now Pat. No. 10,064,934, which is a continuation of application No. PCT/US2016/058327, filed on Oct. 21, 2016.

(60) Provisional application No. 62/247,362, filed on Oct. 28, 2015, provisional application No. 62/247,394, filed on Oct. 28, 2015, provisional application No. 62/247,483, filed on Oct. 28, 2015, provisional application No. 62/247,297, filed on Oct. 28, 2015, provisional application No. 62/244,802, filed on Oct. 22, 2015, provisional application No. 62/244,946, filed on Oct. 22, 2015, provisional application No. 62/244,837, filed on Oct. 22, 2015, provisional application No. 62/244,813, filed on Oct. 22, 2015, provisional application No. 62/245,031, filed on Oct. 22, 2015.

(51) **Int. Cl.**

A61P 11/00	(2006.01)
A61K 39/12	(2006.01)
A61K 39/215	(2006.01)
A61K 39/155	(2006.01)
C07K 16/10	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**
CPC ***A61K 39/155*** (2013.01); ***A61K 39/12*** (2013.01); ***A61K 39/215*** (2013.01); ***A61P 11/00*** (2018.01); ***C07K 16/10*** (2013.01); ***C07K 16/1027*** (2013.01); ***A61K 2039/53*** (2013.01); ***A61K 2039/55511*** (2013.01); ***A61K 2039/55555*** (2013.01); ***A61K 2039/6018*** (2013.01); ***A61K 2039/70*** (2013.01); ***C07K 2317/76*** (2013.01); ***C12N 2760/18034*** (2013.01); ***C12N 2760/18331*** (2013.01); ***C12N 2760/18434*** (2013.01); ***C12N 2760/18534*** (2013.01); ***C12N 2760/18634*** (2013.01); ***C12N 2770/20034*** (2013.01); ***Y02A 50/381*** (2018.01); ***Y02A 50/39*** (2018.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,906,092	A	9/1975	Hillman et al.
4,790,987	A	12/1988	Compans et al.
5,169,628	A	12/1992	Wathen
5,427,782	A	6/1995	Compans et al.
6,235,691	B1	5/2001	Klein et al.
6,500,419	B1	12/2002	Hone et al.
6,514,948	B1	2/2003	Raz et al.
7,001,890	B1	2/2006	Wagner et al.
7,208,161	B1	4/2007	Murphy et al.
7,449,324	B2	11/2008	Fouchier et al.
7,531,342	B2	5/2009	Fouchier et al.
7,671,186	B2	3/2010	Klein et al.
7,704,729	B2	4/2010	Tang et al.
8,217,016	B2	7/2012	Hoerr et al.
8,252,289	B2	8/2012	Elevuri et al.
8,710,200	B2	4/2014	Schrum et al.
8,722,341	B2	5/2014	Fouchier et al.
8,734,853	B2	5/2014	Sood et al.
8,754,062	B2	6/2014	De Fougerolles et al.
8,822,663	B2	9/2014	Schrum et al.
8,841,433	B2	9/2014	Fouchier et al.
8,889,145	B2	11/2014	Blain et al.
8,937,206	B2	1/2015	De Jong et al.
8,999,380	B2	4/2015	Bancel et al.
9,192,661	B2	11/2015	Jain et al.
9,221,891	B2	12/2015	Bancel et al.
9,283,287	B2	3/2016	Bancel et al.
9,303,079	B2	4/2016	Bancel et al.
9,378,728	B2	6/2016	Fouchier et al.
9,464,124	B2	10/2016	Bancel et al.
9,512,455	B2	12/2016	Wang et al.
9,567,653	B2	2/2017	Fouchier et al.
9,597,380	B2	3/2017	Chakraborty et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2473135	6/2003
EP	1026253	8/2000

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 16/036,318, filed Jul. 16, 2018, Ciaramella et al.

(Continued)

Primary Examiner — Nicole Kinsey White
(74) *Attorney, Agent, or Firm* — Wolf, Greenfield & Sacks, P.C.

(57) **ABSTRACT**

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

26 Claims, 24 Drawing Sheets
Specification includes a Sequence Listing.

The collaboration between Moderna and Niaid directed by Fauci in 2015 and the patent registration of the anti-Covid vaccine of 28 March 2019

The patent is updated on 7 July 2020 but was registered for the first time on 28 February 2020 but in continuation of the previous registration of 28

March 2019: the only one not to have changed the patent number (Pat. No.) as is see in the historical extract of the vaccine.

“Continuation of aplication No. 16 / 368,270, filed on Mar.28,2019, which is a continuation of aplication No. 16 / 040,981, filed on Jul.20,2018, now Pat.No. 10,272,150, which is a continuation of aplication No. 15 / 674,599, filed on Aug.1,2017, now Pat.No.10,064,934, which is a continuation of aplication No.PCT / US2016 / 058327, filed on Oct.21,2016 “.

THE EXCHANGE OF DOCUMENTS ON DECEMBER 2019

Analogues suspected on the existence of an experimental gene serum from Moderna before the official discovery of the Wuhan-Hu-1 virus, later identified as a new coronavirus initially named 2019-nCoV because the first cases were recorded in the populated city of Hubei precisely in that year, which was isolated and sequenced as Wuhan MN908947.1 on January 5, 2020.

The first to report the macroscopic anomaly was the

British online investigative newspaper The Daily Exposé: «The first to report the macroscopic anomaly was the British online investigative newspaper The Daily Exposé. “A confidentiality agreement shows that potential coronavirus vaccine candidates were transferred from Moderna to the University of North Carolina in 2019, nineteen days before the emergence of the alleged virus causing Covid-19 in Wuhan, China» wrote the British media on June 18, 2021.



Confidential Disclosure Agreement

In order to protect confidential information relating to research, development, business plans, and other technology, which may be disclosed between them, the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health ("NIAID"), and the "Collaborator" identified below (individually, a "Party"; collectively the "Parties"), intending to be legally bound as of the date of the last signature hereto ("Effective Date"), agree that:

1. A Party ("Disclosing Party") may disclose information to the other ("Receiving Party") for the purpose of assessing their interest in research collaboration (the "Purpose"). The Disclosing Parties are: **NIAID; Moderna Therapeutics, Inc. and its affiliates,** Proprietary info (the "Collaborator").

2. The Parties' representatives for disclosing or receiving information (if known):

For NIAID: Barney Graham and other employees and contractors of NIAID as needed to fulfill the Purpose.

For Collaborator: Giuseppe Ciaramella, Stephane Bancel, Lee Cooper, and other employees of the Collaborator as needed to fulfill the Purpose

3. The information disclosed under this Agreement ("Confidential Information") includes any and all technical, business and financial information, including third party information, relating to the Disclosing Party, including but not limited to: (a) non-public patent applications; Proprietary info and (c) other proprietary information, ideas, gene sequences, samples, chemical compounds, biological materials, techniques, works of authorship, non-public inventions, know-how and processes related to the current, future, and proposed products and/or services of the Disclosing Party or its partners, and including without limitation, information concerning research, experimental work, development, design details and specifications, engineering, financial information, procurement requirements, purchasing, manufacturing, customer lists, investors, employees, business and contractual relationships, business forecasts, analyst reports, marketing plans and any additional non-public information that the Disclosing Party provides.

The Confidential Information disclosed under this Agreement is described as:

For NIAID: NIAID's proprietary information and data relating to the development of vaccines for HIV, influenza, Ebola and MERS and development of broadly neutralizing monoclonal antibodies for preventative and therapeutic use.

For Collaborator: Moderna's proprietary and confidential information related to design and manufacture of a messenger RNA platform and messenger RNA constructs for treatment and prevention of disease.

4. The Receiving Party will not disclose the Confidential Information of the Disclosing Party to any person except its employees, consultants, contractors, directors, or professional advisors or authorized representatives to whom it is necessary to disclose the Confidential Information for the Purpose described above, and any such disclosures shall be under terms at least as restrictive as those specified herein. Any of the persons mentioned above who are given access to the Confidential Information shall be informed of this Agreement. The Receiving Party shall protect the Confidential Information by using the same degree

{00016216.1} Confidential Disclosure Agreement Moderna Therapeutics, Inc./VRC
NIAID Ref. No. 2015-33448 Page 1 of 4

MATERIAL TRANSFER AGREEMENT
SIGNATURE PAGE

FOR RECIPIENT:

Recipient's Investigator
Ralph Baric, PhD
Professor
Date: 12/12/2019
Mailing Address for Materials:
Attention: Dr. Rachel Graham, Department of Epidemiology, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB #7435, Chapel Hill, NC 27599-7435
Tel:919-966-3895 Fax:

Duly Authorized
Jacqueline Quay
Director, Licensing & Innovation Support, OTC
Date: 12/16/19
Mailing Address for Notices:
The University of North Carolina at Chapel Hill
Office of Technology Commercialization
109 Church Street, Chapel Hill, NC 27516
Tel: 919-966-3929 Fax: 919-962-0646

FOR PROVIDERS:

NIAID's Investigator
Barney Graham, MD, PhD
Date:

Duly Authorized
Amy F. Petrik-S Digitally signed by Amy F. Petrik-S Date: 2019.12.13 08:05:21 -05'00'
Amy Petrik, PhD
Technology Transfer Specialist, TTIPO, NIAID
Date:
Mailing Address for Notices:
Technology Transfer and Intellectual Property Office
National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
Suite 6D, MSC 9804
5601 Fishers Lane
Rockville, MD 20852
Tel: 301/496-2644 Fax: 240-627-3117

Moderna's Investigator
Sunny Himansu, PhD
Date: 12/17/2019

Duly Authorized
Shaun Ryan
Deputy General Counsel
Date: 12/17/19
Mailing Address for Notices:
ModernaTX, Inc.
200 Technology Square
Cambridge, MA 20139
Attn: General Counsel

The confidential agreement of Moderna and NIAID

«The confidentially agreement (like at the bottom of

the page) states that providers 'Moderna' alongside the 'National Institute of Allergy and Infectious Diseases' (NIAID) agreed to tranfer 'mRNA coronavirus vaccine candidates' developed and jointly-owned by NIAID and Moderna to recipients 'The Universisty of North Carolina at Chapel Hill' on the 12th December 2019» wrote the editorial staff of Exposé publishing the extracts on pages 105 and 108.

«The material transfer agreement was signed the December 12th 2019 by Ralph Baric, PhD, at the University of North Carolina at Chapel Hill (the microbiologist of the laboratory chimeric SARS virus experiments – ed), and then signed by Jacqueline Quay, Director of Licensing and Innovation Support at the University of North Carolina on December 16th 2019» adds the online newspaper, then asking inevitable questions…

PANDEMIC EMERGENCY, WAR IN UKRAINE AND APOCALYPSE

«So why was an mRNA coronavirus vaccine candidate developed by Moderna being transferred

to the University of North Carolina on December 12th 2019? Perhaps Moderna and the National Institute of Allergy and Infectious Diseases would like to explain themselves in a court of law?».

Questions similar to those I asked myself in an interview with TG6 journalist Anna Turletti in which I asked myself: “When will Bill Gates, great director of dangerous research on laboratory SARS viruses in Wuhan and financier of Big Pharma, be arrested of the consequent vaccines? Is there only one magistrate on earth, only one, willing to do so in the face of these serious, precise and consistent evidence of a diabolical plan?”.

This pandemic has been “planned for decades by Fauci and Gates”, also according to the lawyer Robert F. Kennedy jr, engaged through his association Chilndren’s Health Defense in the fight against vaccines without adequate testing also inoculated to minors, as shamelessly admitted by the Pfizer itself in relation to the lack of data on myocardial risks for children under the age of 5.

But the manipulation of the viral load in the toxic protein Spike, as revealed by Colonel Lawrence

Sellin, former researcher in the bacteriological laboratories of the US Army of Fort Detrick Frederick (Mariland), could be the cause of a similar toxicity of vaccines suitable to explain the reactions. serious or even fatal adverse events.

This pandemic was also functional to the world health dictatorship and therefore strategically preparatory to the Dictatorship of the New World Order and the imposition of the economic Great Reset, concretely feasible only through a real famine in the rich West and a Third World War such as the one that could derive from the conflict in Ukraine.

Certainly the last Great War on planet earth: before the Apocalypse!

Fabio Giuseppe Carlo Carisio

follow ***Gospa News on Telegram***

.